OSI-420 50mg
50mg
| Purity Not Available
Adooq Bioscience
OSI-420 (Desmethyl Erlotinib,CP-473420) is an orally active EGFR tyrosin kinase inhibitor, which inhibits receptor tyrosine kinases (TKs) by inhibition of the intercellular domain .
More Information
Supplier Page
OSI-420 5mg
5mg
| Purity Not Available
Adooq Bioscience
OSI-420 (Desmethyl Erlotinib,CP-473420) is an orally active EGFR tyrosin kinase inhibitor, which inhibits receptor tyrosine kinases (TKs) by inhibition of the intercellular domain .
More Information
Supplier Page
Adooq Bioscience
OSI-420 (Desmethyl Erlotinib,CP-473420) is an orally active EGFR tyrosin kinase inhibitor, which inhibits receptor tyrosine kinases (TKs) by inhibition of the intercellular domain .
More Information
Supplier Page
OSI-420 100mg
100mg
| Purity Not Available
Adooq Bioscience
OSI-420 (Desmethyl Erlotinib,CP-473420) is an orally active EGFR tyrosin kinase inhibitor, which inhibits receptor tyrosine kinases (TKs) by inhibition of the intercellular domain .
More Information
Supplier Page
OSI-420 10mg
10mg
| Purity Not Available
Adooq Bioscience
OSI-420 (Desmethyl Erlotinib,CP-473420) is an orally active EGFR tyrosin kinase inhibitor, which inhibits receptor tyrosine kinases (TKs) by inhibition of the intercellular domain .
More Information
Supplier Page
Adooq Bioscience
OSI-930 5mg
5mg
| Purity Not Available
Adooq Bioscience
OSI-930 is a potent inhibitor of Kit, KDR, Flt, CSF-1R, c-Raf and Lck with IC50 of 80 nM, 9 nM, 8 nM, 15 nM, 41 nM and 22 nM, respectively.
More Information
Supplier Page
OSI-930 50mg
50mg
| Purity Not Available
Adooq Bioscience
OSI-930 is a potent inhibitor of Kit, KDR, Flt, CSF-1R, c-Raf and Lck with IC50 of 80 nM, 9 nM, 8 nM, 15 nM, 41 nM and 22 nM, respectively.
More Information
Supplier Page
Adooq Bioscience
OSU-03012 is a novel celecoxib derivative, without cyclooxygenase-2 inhibitory activity, capable of inducing apoptosis in various cancer cells types.
More Information
Supplier Page
OSU-03012 5mg
5mg
| Purity Not Available
Adooq Bioscience
OSU-03012 is a novel celecoxib derivative, without cyclooxygenase-2 inhibitory activity, capable of inducing apoptosis in various cancer cells types.
More Information
Supplier Page